Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM · Healthcare

₹4,750.00+0.85%06 Nov 2026

Ask the data

Instant answers about Torrent Pharmaceuticals Ltd. — computed from its filings, no language model

Market cap₹1,80,671 cr

Current price₹4,750.00

High / Low₹5,123 / ₹3,553

P/E85.1

P/B9.83

Book value₹483.0

ROE11.6%

ROCE11.5%

Debt / equity0.76

Dividend yield0.71%

EPS (TTM)₹55.84

Face value₹5

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	6,002	7,673	7,939	8,005	8,508	9,620	10,728	11,516	13,980
EBITDA	1,349	1,984	2,170	2,485	2,431	2,842	3,368	3,721	4,559
Operating margin	22.5%	25.9%	27.3%	31.0%	28.6%	29.5%	31.4%	32.3%	32.6%
Interest	308	504	451	358	255	333	354	252	385
Depreciation	409	618	654	658	662	707	808	795	1,119
Profit before tax	931	562	1,187	1,526	1,226	1,847	2,352	2,673	2,872
Tax	253	126	162	274	449	602	696	762	734
Net profit	678	436	1,025	1,252	777	1,245	1,656	1,911	2,163
EPS ₹	40.07	25.78	60.55	73.98	45.93	36.79	48.94	56.47	63.92
Operating cash flow	—	—	—	—	1,803	2,368	3,266	2,585	3,023
Capex	—	—	—	—	203	574	433	611	677
Dividend paid	—	—	—	—	677	863	1,015	1,083	1,289
Total assets	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312
Equity	4,622	4,724	4,823	5,837	5,953	6,198	6,856	7,591	8,389

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	1,722	1,872	1,894	2,051	1,856	2,022	2,005	1,966	1,946	2,056	2,017	1,995	1,937	2,134	2,137	2,108	2,131	2,291	2,491	2,491	2,591	2,660	2,732	2,745	2,859	2,889	2,809	2,959	3,178	3,302	3,303	4,197	4,921	4,979
Operating profit	364	477	473	561	473	541	541	540	548	661	635	607	582	677	660	538	561	679	724	727	791	825	869	883	904	939	914	964	1,032	1,083	1,088	1,356	1,664	1,666
Operating margin	21.1%	25.5%	25.0%	27.4%	25.5%	26.8%	27.0%	27.5%	28.2%	32.1%	31.5%	30.4%	30.0%	31.7%	30.9%	25.5%	26.3%	29.6%	29.1%	29.2%	30.5%	31.0%	31.8%	32.2%	31.6%	32.5%	32.5%	32.6%	32.5%	32.8%	32.9%	32.3%	33.8%	33.5%
Other income	42	27	10	3	17	20	34	53	15	4	6	8	39	40	51	48	56	16	-10	9	34	26	-33	31	24	-16	33	-18	-37	-27	-13	-17	-12	-10
Interest	121	122	126	133	123	122	116	111	102	102	92	91	73	68	71	62	57	69	102	107	103	91	80	80	75	64	57	56	56	48	45	236	305	300
Depreciation	151	150	152	156	160	160	163	163	168	161	165	167	165	165	168	167	162	163	193	196	191	201	213	203	197	198	199	201	201	204	206	508	593	609
Profit before tax	134	232	205	275	-150	279	296	319	293	402	384	357	383	484	472	357	-87	463	419	433	531	559	631	631	656	661	691	665	738	791	814	529	733	737
Tax	-94	69	26	29	2	63	52	68	-21	81	74	60	59	154	156	108	31	151	136	146	153	173	188	182	199	208	188	167	190	200	179	165	167	203
Net profit	228	163	179	246	-152	216	244	251	314	321	310	297	324	330	316	249	-118	312	283	287	378	363	442	449	457	453	503	498	548	591	635	389	566	534
EPS ₹	13.55	9.66	10.57	14.50	-8.95	12.74	14.48	14.77	18.56	18.98	18.32	17.52	19.16	19.53	18.63	14.75	-6.98	9.22	8.36	8.48	11.18	11.39	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.45	18.77	11.51	14.87	14.05
Revenue YoY	—	—	—	—	7.8%	8.0%	5.9%	-4.1%	4.8%	1.7%	0.6%	1.5%	-0.5%	3.8%	5.9%	5.7%	10.0%	7.2%	18.2%	16.9%	—	16.1%	9.7%	10.2%	10.3%	8.6%	2.8%	7.8%	11.2%	14.3%	17.6%	41.8%	54.8%	50.8%
Profit YoY	—	—	—	—	-166.7%	32.5%	36.3%	2.0%	—	48.6%	27.0%	18.3%	3.2%	2.8%	1.9%	-16.2%	-136.4%	-1.3%	13.7%	—	—	16.3%	56.2%	56.4%	20.9%	24.8%	13.8%	10.9%	19.9%	30.5%	26.2%	-21.9%	3.3%	-9.6%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Torrent Pharmaceuticals Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	1,180	1,449	1,778	2,082	2,767	3,365	3,476	5,416	4,587
Operating profit	248	413	422	400	680	1,059	844	2,627	1,127
Operating margin	21.0%	28.5%	23.8%	19.2%	24.6%	31.5%	24.3%	48.5%	24.6%
Other income	9	9	8	113	132	36	305	277	299
Interest	—	—	—	18	37	58	173	182	202
Depreciation	37	54	58	64	72	79	180	221	269
Profit before tax	191	314	358	371	665	958	796	2,554	955
Tax	4	106	67	59	119	196	173	656	101
Net profit	187	207	291	311	546	762	623	1,898	854

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	253	252	221	282	287	321	290	361	375	356	357	418	482	460	418	511	508	518	545	649	689	658	770	885	793	733	954	917	856	806	897	1,867	1,564	999	986	1,318	1,058	1,249	962	847	1,026	1,041
Operating profit	49	63	27	61	59	78	51	99	118	101	96	118	136	98	71	141	105	89	65	144	158	129	249	287	262	172	338	374	171	153	146	1,174	925	312	216	467	244	306	110	121	236	259
Operating margin	19.4%	25.1%	12.0%	21.4%	20.4%	24.3%	17.7%	27.5%	31.5%	28.3%	26.7%	28.2%	28.1%	21.3%	17.0%	27.6%	20.6%	17.2%	12.0%	22.1%	22.9%	19.6%	32.3%	32.4%	33.0%	23.5%	35.4%	40.8%	20.0%	19.0%	16.3%	62.9%	59.1%	31.2%	21.9%	35.4%	23.1%	24.5%	11.4%	14.3%	23.0%	24.9%
Other income	7	11	10	6	2	2	-2	2	1	2	4	2	2	2	2	2	4	7	99	58	58	0	15	14	3	10	9	56	76	72	101	75	97	65	40	49	59	71	120	109	91	81
Interest	5	5	5	6	6	4	—	—	6	3	5	—	4	4	4	4	4	1	9	10	9	7	10	8	15	16	19	24	52	50	47	56	47	41	38	48	51	46	57	55	51	71
Depreciation	8	8	8	8	9	9	11	10	11	11	23	13	14	15	16	15	16	16	17	16	16	19	20	19	20	20	20	19	53	53	55	54	55	55	57	61	64	68	76	74	78	89
Profit before tax	43	62	23	53	46	58	34	88	102	75	49	104	120	81	53	125	89	80	77	175	190	103	197	274	230	146	308	387	142	122	145	1,139	973	281	161	407	188	263	97	101	198	180
Tax	5	8	-8	2	2	2	-1	69	22	12	4	21	23	15	9	26	19	18	-3	27	28	20	44	60	48	32	56	82	30	19	42	309	244	63	40	70	19	29	-17	17	40	160
Net profit	37	54	31	52	44	56	35	19	80	63	45	83	97	66	44	99	70	62	80	148	162	84	153	214	182	114	252	305	112	103	103	830	729	218	121	337	169	234	114	84	158	20
EPS ₹	4.41	6.40	3.64	6.09	5.23	6.62	4.13	2.26	9.49	7.47	5.28	9.82	11.51	7.79	5.25	11.75	8.30	7.27	9.46	17.44	19.15	9.91	18.08	25.28	10.78	6.74	14.89	18.01	6.65	6.05	6.12	49.07	43.07	12.85	7.17	19.95	9.96	13.78	6.79	4.97	9.31	1.25
Revenue YoY	—	—	—	—	13.5%	27.2%	30.8%	27.8%	30.5%	11.0%	23.5%	16.0%	28.5%	29.1%	17.1%	22.1%	5.4%	12.8%	30.1%	27.1%	35.6%	27.0%	41.4%	36.3%	15.1%	11.3%	23.9%	3.6%	7.9%	10.0%	-6.0%	103.6%	82.7%	23.9%	9.9%	-29.4%	-32.4%	25.0%	-2.4%	-35.7%	-3.0%	-16.7%
Profit YoY	—	—	—	—	18.7%	3.4%	13.4%	-62.9%	81.4%	12.9%	27.9%	334.6%	21.2%	4.3%	-0.5%	19.6%	-27.8%	-6.7%	80.1%	48.4%	130.8%	36.3%	91.1%	45.1%	12.3%	36.0%	64.7%	42.5%	-38.5%	-9.6%	-59.1%	172.1%	550.9%	111.7%	17.5%	-59.4%	-76.8%	7.3%	-5.8%	-75.1%	-6.5%	-91.5%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 28 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	17.7%	9.2%	10.4%	11.7%	11.8%	21.3%	23.4%	24.8%	25.8%	21.4%	21.6%	21.7%	20.9%	13.1%	20.3%	19.5%	21.9%	23.8%	25.0%	24.0%	24.8%	25.2%	26.4%	25.3%	26.9%	25.8%	26.0%	11.6%
ROCE	13.0%	11.1%	11.6%	12.5%	12.7%	17.8%	18.9%	19.6%	19.8%	17.7%	18.1%	18.7%	18.5%	14.9%	19.4%	21.1%	22.8%	25.1%	26.0%	27.3%	27.6%	27.6%	28.1%	28.1%	29.1%	14.0%	15.1%	11.5%
Net margin	10.8%	5.7%	6.3%	7.0%	7.1%	12.9%	14.2%	15.0%	15.5%	15.6%	15.6%	15.4%	14.7%	9.1%	12.8%	12.8%	14.0%	15.2%	15.6%	16.0%	16.5%	16.6%	16.9%	17.5%	17.8%	15.5%	13.9%	12.2%
EBITDA margin	24.9%	25.9%	26.2%	26.7%	26.7%	27.3%	28.7%	29.9%	30.6%	31.0%	30.9%	30.8%	29.5%	28.6%	29.6%	30.0%	30.7%	31.4%	31.7%	32.0%	32.2%	32.3%	32.5%	32.6%	32.7%	32.6%	33.0%	33.2%
Debt / equity	1.24	1.03	1.03	1.03	1.03	0.91	0.91	0.91	0.91	0.83	0.83	0.83	0.83	0.67	0.85	0.66	0.66	0.57	0.57	0.41	0.41	0.40	0.40	0.31	0.31	1.76	1.76	0.76
Interest coverage	2.69	2.12	2.21	2.42	2.58	3.63	4.04	4.43	4.71	5.26	5.96	6.60	7.19	5.75	5.85	5.82	6.65	7.64	8.60	9.63	10.56	11.61	12.82	14.29	15.67	8.46	5.52	4.17
Asset turnover	0.53	0.54	0.55	0.56	0.56	0.57	0.57	0.57	0.57	0.57	0.57	0.58	0.59	0.65	0.66	0.69	0.71	0.71	0.73	0.74	0.75	0.77	0.79	0.79	0.82	0.32	0.35	0.39

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	85	85	85	85	85	85	85	85	85	169	169	169	169	169	169	169	169	190
Other equity / reserves	1,818	2,406	3,409	4,266	4,538	4,640	4,739	5,753	5,868	5,922	6,029	6,538	6,687	7,335	7,422	8,280	8,220	18,183
Total equity	1,902	2,491	3,494	4,350	4,622	4,724	4,823	5,837	5,953	6,091	6,198	6,707	6,856	7,504	7,591	8,449	8,389	18,373
Borrowings	955	2,504	1,853	2,241	5,737	4,847	4,366	4,825	4,018	4,018	5,297	4,416	3,938	3,048	3,026	2,590	14,798	13,874
Current liabilities	2,175	2,824	3,285	2,738	5,202	5,165	5,454	4,892	4,415	3,950	5,447	4,898	5,426	4,847	4,717	4,435	8,343	7,984
Non-current liabilities	992	2,589	2,278	2,613	4,418	4,231	3,732	3,346	2,732	3,178	3,367	3,139	2,779	2,737	2,682	2,631	18,384	18,258
Total assets	5,070	7,904	9,058	9,702	14,243	14,121	14,010	14,075	13,100	13,219	15,012	14,744	15,061	15,088	14,990	15,515	44,312	44,615
Property, plant & equipment	847	922	975	1,871	2,417	2,801	2,818	2,758	2,575	2,741	2,772	3,192	3,297	3,217	3,455	3,458	4,909	5,066
Capital work-in-progress	534	678	1,042	463	423	479	577	744	544	609	688	263	281	412	367	488	457	404
Investments	186	298	780	804	492	353	2	181	226	505	199	277	173	127	156	133	949	2,160
Inventories	1,006	1,067	1,358	1,559	1,966	1,935	2,148	2,681	2,462	2,328	2,230	2,218	2,279	2,271	2,541	2,467	3,138	3,182
Receivables	1,099	1,587	1,445	951	1,253	1,436	1,649	1,523	1,632	1,754	1,944	1,752	1,844	1,783	1,867	2,185	3,031	3,398
Cash & equivalents	769	567	284	279	241	589	662	573	398	343	508	538	835	1,146	573	621	1,117	891

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 13 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	599	810	2,742	1,009	894	1,798	1,393	2,005	1,803	2,368	3,266	2,585	3,023
Cash from investing	-356	-2,162	-838	-787	-4,707	-241	199	-449	-198	-2,356	-168	-540	-12,713
Cash from financing	86	1,212	-1,435	-193	3,417	-1,314	-1,549	-1,651	-1,781	77	-2,779	-2,298	10,151
Capex	400	243	599	487	791	663	407	335	203	574	433	611	677
Free cash flow	199	568	2,143	522	103	1,135	986	1,670	1,600	1,794	2,833	1,974	2,346
Dividends paid	267	200	840	—	—	—	—	338	677	863	1,015	1,083	1,289

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹5,066 cr11%

CWIP

₹404 cr1%

Investments

₹2,160 cr5%

Inventories

₹3,182 cr7%

Receivables

₹3,398 cr8%

Cash & equivalents

₹891 cr2%

Other assets

₹29,514 cr66%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Bullish setup · 7/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+0.7%

6 months+8.9%

1 year+32.0%

3Y CAGR+34.2%

5Y CAGR+26.8%

10Y CAGR+21.7%

50-day avg₹4,783.25

200-day avg₹4,528.58

RSI (14)66

Long-term financials (FY14–FY15)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY15	₹3,418 Cr	₹796 Cr	₹623 Cr
FY14	₹3,228 Cr	₹958 Cr	₹762 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Torrent Pharmaceuticals Ltd. with

Sun Pharmaceutical Industries vs Torrent Pharmaceuticals Divi's Laboratories vs Torrent Pharmaceuticals Torrent Pharmaceuticals vs Laurus Labs Torrent Pharmaceuticals vs Apollo Hospitals Enterprise Torrent Pharmaceuticals vs Zydus Lifesciences

FAQs

What is the share price of Torrent Pharmaceuticals Ltd.?

Torrent Pharmaceuticals Ltd. (TORNTPHARM) closed at ₹4,750.00 on NSE on 06 Nov 2026.

What is the market cap of Torrent Pharmaceuticals Ltd.?

₹1,80,671 crore at the latest close.

What is the P/E ratio of Torrent Pharmaceuticals Ltd.?

85.1, on trailing-twelve-month earnings from its filings.

How fast is Torrent Pharmaceuticals Ltd. growing?

Torrent Pharmaceuticals Ltd.: revenue has compounded at 13.3% a year over three years; net profit at 20.2% a year. Latest-quarter revenue is up 50.8% year on year, profit down 9.6%.

How profitable is Torrent Pharmaceuticals Ltd.?

On a trailing-twelve-month basis return on equity is 11.6%, return on capital employed 11.5%, operating margin 33.2%, net margin 12.2%.

How much debt does Torrent Pharmaceuticals Ltd. have?

Torrent Pharmaceuticals Ltd. is moderately geared: debt to equity is 0.76 with borrowings of ₹13,874 cr against cash of ₹891 cr (balance sheet of 2026-09-30). Operating profit covers interest 4.2 times.

Financials parsed from Torrent Pharmaceuticals Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.